Melphalan

• 

  Subject Areas on Research

  • "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma. 
  • A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer. 
  • A multi-institution experience comparing the clinical and physiologic differences between upper extremity and lower extremity melphalan-based isolated limb infusion. 
  • A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. 
  • A multi-institutional experience of repeat regional chemotherapy for recurrent melanoma of extremities. 
  • A phase 1 study of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with locally advanced in-transit malignant melanoma. 
  • A phase I multi-institutional study of systemic sorafenib in conjunction with regional melphalan for in-transit melanoma of the extremity. 
  • A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results. 
  • A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma. 
  • ANZCCSG BabyBrain99; intensified systemic chemotherapy, second look surgery and involved field radiation in young children with central nervous system malignancy. 
  • Adjuvant chemotherapy in primary treatment of osteogenic sarcoma. A Southwest Oncology Group study. 
  • Advanced prostatic carcinoma: pulmonary manifestations. 
  • Age and the treatment of multiple myeloma. Southeastern Cancer Study Group experience. 
  • Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial. 
  • Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome. 
  • Bevacizumab-induced alterations in vascular permeability and drug delivery: a novel approach to augment regional chemotherapy for in-transit melanoma. 
  • Burden of disease predicts response to isolated limb infusion with melphalan and actinomycin D in melanoma. 
  • Busulfan therapy of central nervous system xenografts in athymic mice. 
  • Busulfan/melphalan/antithymocyte globulin followed by unrelated donor cord blood transplantation for treatment of infant leukemia and leukemia in young children: the Cord Blood Transplantation study (COBLT) experience. 
  • Chemotherapy of subcutaneous and intracranial human medulloblastoma xenografts in athymic nude mice. 
  • Clinical pharmacology of melphalan and its implications for clinical resistance to anticancer agents. 
  • Clinicopathologic review of enucleated eyes after intra-arterial chemotherapy with melphalan for advanced retinoblastoma. 
  • Combination chemotherapy for primary amyloidosis reconsidered. 
  • Comparison of two long-term chemotherapy regimens, with or without agents to modify skeletal repair, in multiple myeloma. 
  • Computed Tomography-Based Limb Volume Measurements for Isolated Limb Infusion in Melanoma. 
  • Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. 
  • Consolidation and maintenance therapy in multiple myeloma: randomized comparison of a new approach to therapy after initial response to treatment. 
  • Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution. 
  • Cyclocreatine in cancer chemotherapy. 
  • Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma. 
  • Defining regional infusion treatment strategies for extremity melanoma: comparative analysis of melphalan and temozolomide as regional chemotherapeutic agents. 
  • Development of a model of melphalan-induced gastrointestinal toxicity in mice. 
  • Dose intensive melphalan and cyclophosphamide with autologous hematopoietic stem cells for recurrent medulloblastoma or germinoma. 
  • Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma. 
  • Effect of O6-benzylguanine on nitrogen mustard-induced toxicity, apoptosis, and mutagenicity in Chinese hamster ovary cells. 
  • Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes. 
  • Elevated DNA polymerase alpha, DNA polymerase beta, and DNA topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is cross-resistant to nitrosoureas and topotecan. 
  • Enhanced melphalan cytotoxicity following buthionine sulfoximine-mediated glutathione depletion in a human medulloblastoma xenograft in athymic mice. 
  • Enhancement of melphalan activity by inhibition of DNA polymerase-alpha and DNA polymerase-beta. 
  • Enhancement of melphalan-induced gastrointestinal toxicity in mice treated with regional hyperthermia and BSO-mediated glutathione depletion. 
  • Enhancing melanoma treatment with resveratrol. 
  • Establishment of a melphalan-resistant rhabdomyosarcoma xenograft with cross-resistance to vincristine and enhanced sensitivity following buthionine sulfoximine-mediated glutathione depletion. 
  • Experimental chemotherapy of human medulloblastoma with classical alkylators. 
  • FOXP3 expression following bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning. 
  • Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant. 
  • Flunarizine enhancement of melphalan activity against drug-sensitive/resistant rhabdomyosarcoma. 
  • Four-cycle high-dose therapy with hematopoietic support for metastatic breast cancer: no improvement in outcomes compared with single-course high-dose therapy. 
  • Future directions in regional treatment strategies for melanoma and sarcoma. 
  • Gene expression signatures as a guide to treatment strategies for in-transit metastatic melanoma. 
  • Glutathione depletion increases the cytotoxicity of melphalan to PC-3, an androgen-insensitive prostate cancer cell line. 
  • Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma. 
  • High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma. 
  • High-dose chemotherapy with autologous stem-cell rescue in children and adults with newly diagnosed pineoblastomas. 
  • High-dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors. 
  • High-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support. A clinical and pharmacologic study. 
  • High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan. 
  • High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies. 
  • High-dose melphalan and cyclophosphamide with autologous bone marrow rescue for recurrent/progressive malignant brain tumors in children: a pilot pediatric oncology group study. 
  • High-dose therapy with autologous hematopoietic cell support as salvage treatment for patients with breast cancer who have relapsed after previous high-dose chemotherapy. 
  • High-dose, double alkylating agent chemotherapy with DTIC, melphalan, or ifosfamide and marrow rescue for metastatic malignant melanoma. 
  • Hyperthermia-induced enhancement of melphalan activity against a melphalan-resistant human rhabdomyosarcoma xenograft. 
  • Hypoxia in melanoma: using optical spectroscopy and EF5 to assess tumor oxygenation before and during regional chemotherapy for melanoma. 
  • Immunotherapy following regional chemotherapy treatment of advanced extremity melanoma. 
  • In-transit melanoma: the role of alkylating-agent resistance in regional therapy. 
  • Increased melphalan activity in intracranial human medulloblastoma and glioma xenografts following buthionine sulfoximine-mediated glutathione depletion. 
  • Intraarterial administration of melphalan for treatment of intracranial human glioma xenografts in athymic rats. 
  • Intrathecal melphalan therapy of human neoplastic meningitis in athymic nude rats. 
  • Intravenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALL. 
  • Intravenous busulfan plus melphalan is a highly effective, well-tolerated preparative regimen for autologous stem cell transplantation in patients with advanced lymphoid malignancies. 
  • Isolated Limb Infusion as a Limb Salvage Strategy for Locally Advanced Extremity Sarcoma. 
  • Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion. 
  • L-amino acid oxidase (LOX) modulation of melphalan activity against intracranial glioma. 
  • Limb preservation with isolated limb infusion for locally advanced nonmelanoma cutaneous and soft-tissue malignant neoplasms. 
  • Management of recurrent melanoma of the extremity. 
  • Managing the complications of plasma cell myeloma. 
  • Marked variability of melphalan plasma drug levels during regional hyperthermic isolated limb perfusion. 
  • Melphalan transport, glutathione levels, and glutathione-S-transferase activity in human medulloblastoma. 
  • Melphalan-induced toxicity in nude mice following pretreatment with buthionine sulfoximine. 
  • Microparticle Drug Delivery in Ophthalmology. 
  • Modulation of melphalan resistance in glioma cells with a peripheral benzodiazepine receptor ligand-melphalan conjugate. 
  • Modulation of resistance to regional chemotherapy in the extremity melanoma model. 
  • Multiple drug chemotherapy regimen for patients with hormonally-unresponsive carcinoma of the prostate: a preliminary report. 
  • Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. 
  • Myeloid neoplasms secondary to plasma cell myeloma: an intrinsic predisposition or therapy-related phenomenon? A clinicopathologic study of 41 cases and correlation of cytogenetic features with treatment regimens. 
  • Neurologic manifestations of essential thrombocythemia. 
  • Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. 
  • Optimizing melphalan pharmacokinetics in regional melanoma therapy: does correcting for ideal body weight alter regional response or toxicity? 
  • Patterns of recurrence following complete response to regional chemotherapy for in-transit melanoma. 
  • Pearls and pitfalls of intraarterial chemotherapy for retinoblastoma. 
  • Pharmacokinetics & drug resistance of melphalan in regional chemotherapy: ILP versus ILI. 
  • Phase I and pharmacokinetic study of docetaxel combined with melphalan and carboplatin, with autologous hematopoietic progenitor cell support, in patients with advanced refractory malignancies. 
  • Phase I study of melphalan alone and melphalan plus whole body hyperthermia in dogs with malignant melanoma. 
  • Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma. 
  • Phase II testing of melphalan in children with newly diagnosed rhabdomyosarcoma: a model for anticancer drug development. 
  • Phase II treatment of medulloblastoma and pineoblastoma with melphalan: clinical therapy based on experimental models of human medulloblastoma. 
  • Phase II trial of intravenous melphalan in advanced colorectal carcinoma. 
  • Plasma cytokine analysis in patients with advanced extremity melanoma undergoing isolated limb infusion. 
  • Predicting disease progression after regional therapy for in-transit melanoma. 
  • Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis. 
  • Prospective multicenter phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with advanced extremity melanoma. 
  • Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. 
  • Re: Toxicity of intrathecal melphalan. 
  • Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT. 
  • Resection of residual disease after isolated limb infusion (ILI) is equivalent to a complete response after ILI-alone in advanced extremity melanoma. 
  • Resolution of primary amyloidosis during chemotherapy. Studies in a patient with nephrotic syndrome. 
  • Role of glutathione in cellular resistance to alkylating agents. 
  • SRC family kinase inhibition as a novel strategy to augment melphalan-based regional chemotherapy of advanced extremity melanoma. 
  • Serial carcinoembryonic antigen assays in patients with metastatic carcinoma of prostate being treated with chemotherapy. 
  • Severe pulmonary toxicity after myeloablative conditioning using total body irradiation: an assessment of risk factors. 
  • Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy. 
  • Synergistic interactions between cyclophosphamide or melphalan and VP-16 in a human rhabdomyosarcoma xenograft. 
  • Targeting N-cadherin enhances antitumor activity of cytotoxic therapies in melanoma treatment. 
  • Targeting N-cadherin increases vascular permeability and differentially activates AKT in melanoma. 
  • Temozolomide is a novel regional infusion agent for the treatment of advanced extremity melanoma. 
  • The effect of L-amino acid oxidase on activity of melphalan against an intracranial xenograft. 
  • The effect of an amino acid-lowering diet on the rate of melphalan entry into brain and xenotransplanted glioma. 
  • The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission. 
  • The role of hyperthermia in regional alkylating agent chemotherapy. 
  • Therapeutic analysis of melphalan-resistant human rhabdomyosarcoma xenograft TE-671 MR. 
  • Unexpected toxicity associated with use of body surface area for dosing melphalan in the dog. 
  • Value of cyclophosphamide or melphalan as combined chemotherapy in hormonally unresponsive prostatic carcinoma. 
  • Verification of supraselective drug delivery for retinoblastoma using intra-arterial gadolinium. 
  • Verification of supraselective drug delivery for retinoblastoma using intra-arterial gadolinium. 
  • Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. 
• 

  Keywords of People

  • Craciunescu, Oana, Associate Professor of Radiation Oncology, Radiation Oncology
  • McLendon, Roger Edwin, Professor of Pathology, Pathology
  • Weinhold, Kent James, Joseph W. and Dorothy W. Beard Professor of Experimental Surgery, in the School of Medicine, Immunology